Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - July 2016


There is growing interest in the field of in vitro 3D models for understanding potential drug-induced toxicity. Models for cardiotoxicity are some of the most sophisticated, with iPSC-derived cardiomyocytes being introduced allowing the tissues to beat in a manner similar to a human heart. Incorporating different cell types into the 3D models also enables multicellular models to be developed to mimic the structural components of the human heart within the body.

Cyprotex has specialist expertise in this field and in July launched a new 3D hypertrophy and structural cardiotoxicity model. The model allows long term repeat dosing over 14 days, and combines a continuous monitoring of hypertrophy, and a terminal assessment of structural cardiotoxicity.

3D Hypertrophy and Cardiotoxicity Assay

In July, Cyprotex launched a new in vitro 3D hypertrophy and structural cardiotoxicity model allowing repeat dosing regimens over extended time periods. The model enables an accurate prediction of potential structural cardiotoxicity by evaluating multiple high content endpoints and continuous monitoring of hypertrophy.

Learn more

3D Hypertrophy and structural cardiotoxicity model
Webinar on 'In vitro Strategies for Regulatory Genotoxicity Testing' - 8th Sept 2016 (3pm BST; 4pm CEST; 10am EST)

Cyprotex offer in vitro OECD genotoxicity testing under GLP for regulatory submissions for pharmaceutical, chemical, cosmetic and personal care industries. In September we will be holding a webinar titled ‘In vitro strategies for regulatory genotoxicity testing’.

OECD and GLP Genotoxicity
Meet us at the EFMC Conference in Manchester

Next month, Cyprotex will be attending the International Symposium on Medicinal Chemistry in Manchester on the 28 Aug-1st Sept 2016. Come and meet with us to discuss your project.

Book a meeting
Meet us at EFMC
TSCA Reform - First Year Implementation Plan Issued by EPA

On 22nd June 2016, President Obama signed the Frank Lautenburg Chemical Safety for the 21st Century Act which brings about major reform to the Toxic Substances Control Act (TSCA). Shortly after on the 29th June, the EPA issued a roadmap of major activities on which it will focus within the first year of implementation of the new legislation. One important aspect of the new Act is the focus on an alternative testing methods strategy with a goal of reducing vertebrate animal testing.

Read the blog article
TSCA Reform with Frank Lautenburg Chemical Safety for the 21st Century Act
All of the Cyprotex Guides are Now Available for Download

Our popular collection of guides began with the ADME Guide in 2009. From there it has grown to four, comprising booklets on Drug-Drug Interaction Regulatory Testing, Mechanistic Toxicity, and most recently, Chemical and Cosmetics Testing. We are delighted to announce the availability of all of our guides for direct download. It's the exact same material, available for free and in an instant.

Download the guides
Free Guides available for Download
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.